Answers are grounded in this paper and cite their sources.
We evaluated HER-2 receptor status by immunocytochemical and immunohistochemical analyses and fluorescence in situ hybridization (FISH) in 51 fine-needle aspiration (FNA) specimens together with the corresponding formalin-fixed, paraffin-embedded (FFPE) tissue samples obtained from surgically resected breast cancers. Three fixation methods were compared: ethanol, formalin, and CytoLyt-ThinPrep (Cytyc, Boxborough, MA). HER-2 was overexpressed and amplified in 8 (16%) of 51 FFPE specimens. Of the 8 cases, gene amplification was observed in 8 FNA specimens (100%) and overexpression in 2 (25%) ethanol-, 4 (50%) CytoLyt-, and 5 (63%) formalin-fixed FNA specimens. Strong pairwise κ association between FISH results performed on FNA specimens and FFPE tissue samples (ethanol fixation, κ = 0.848; ThinPrep, κ = 0.918) and moderate (ThinPrep, κ = 0.692; formalin fixation, κ = 0.667) to poor (ethanol, κ = 0.300) pairwise κ agreement between tissue immunohistochemical and FNA immunocytochemical results was demonstrated. We conclude that HER-2 protein expression on cytologic preparations was insufficiently reliable for clinical use, whereas HER-2 gene amplification determined by FISH demonstrated strong and consistent correlation with HER-2 status of FFPE tissue samples.
No takes yet. Share an insight, caveat, or question.
Beatty et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: